Research Articles | Page 6 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia Apr 2023 Blood Advances Myelodysplastic Syndromes (MDS)
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes Mar 2024 Clinical Lymphoma, Myeloma & Leukemia Myelodysplastic Syndromes (MDS)
Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years Oct 2019 Blood Advances Aplastic Anemia
Silver lining: reduced relapse with chronic GVHD after transplant for MDS Oct 2020 Clinical Cancer Research: an official Journal of the American Association of Cancer Research Graft Versus Host Disease (GVHD), Myelodysplastic Syndromes (MDS)
Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. Mar 2019 Haematologica Paroxysmal Nocturnal Hemoglobinuria (PNH)
SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM) Apr 2020 Blood Myelodysplastic Syndromes (MDS)
SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes Jun 2020 Clinical Lymphoma , Myeloma & Leukemia Myelodysplastic Syndromes (MDS)
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria Jul 2020 Blood Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH)
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria May 2020 Blood Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH)
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study Apr 2024 Advances in Therapy Paroxysmal Nocturnal Hemoglobinuria (PNH)